News

|

Feeds

|

Email

DUBLIN, Dec. 24, 2021 /PRNewswire/ -- The "Sustained Release Injectables" report has been added to ResearchAndMarkets.com's offering.

https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

The goal of this report is to address the requirement for patient-dependent, and therefore compliance-sensitive, drug treatment protocols such as multiple dosing through controlled release formulations that provide the desired therapeutic effect with dosing of once-a-day or less.

Chronic conditions require drug administration over long periods of time, placing a greater emphasis on self-administration. With the shift away from caregiver interaction, drug safety and compliance/adherence become prominent concerns.

These concerns, which are not new, are becoming magnified as the number of powerful new drugs reaching the market increases. For healthcare managers and public health officials, one way to address these issues is less frequent dosing.

Using formulation technologies designed to modulate the effect of therapeutic substances, drug developers are creating formulations that exhibit extended-release profiles. These chemistries include polymers such as polyethylene glycol-complexed (PEGylated), which are used to product encapsulated and coated versions of new APIs.

What You Will Learn

    --  What are the marketed sustained release injectable drug products, what
        sustained release formulation technologies are used, and who markets
        them?
    --  What are the major factors driving sustained release injectable drug
        demand?
    --  What sustained release injectable drug candidates are in late-stage
        clinical development and what is their potential impact?
    --  How important are drug developer-formulation technologist relationships
        in the sustained release market segment, and what are the key alliances
        in the industry?
    --  What are the essential formulation factors, delivery device selection
        issues, related technology factors and market development issues for
        sustained release injectable drug products?
    --  In what therapeutic market segments do sustained release injectables
        compete? What is their market share today? What will it be in 2028? What
        is their expected growth rate?
    --  What are the significant economic, technology, and regulatory factors
        affecting the market for sustained release injectables?

Key Topics Covered:

Executive Summary

    --  Injectable Drug Market Dynamics
    --  The Trend toward Self-Administration
    --  Injectable Drug Formulation Technology
    --  Innovation in Injectable Device Designs
    --  Therapeutic Demand Drivers

Market Factors

    --  Competitive Landscape
    --  Risk Factors

Sustained Release - Branded Formulation Technologies

    --  Biodegradable Polymers
    --  Branded SR Formulation Technologies
    --  Physical Process Control Methods

Sustained Release Injectables - Development Factors

    --  Formulation Factors
    --  Stability
    --  Lyophilization
    --  Packaging
    --  Administration Factors

SR Injectables - Product Analysis & Market Sector Forecasts

Addiction

    --  Naltrexone
    --  Diabetes
    --  Exenatide

Infectious Disease

    --  Interferon

Hormone Deficiency

    --  Estradiol
    --  Somatropin
    --  Testosterone

Metabolic Diseases

    --  Acromegaly
    --  Lanreotide
    --  Octreotide

Neurology

    --  Aripiprazole
    --  Fluphenazine
    --  Haloperidol
    --  Paliperidone
    --  Olanzapine
    --  Risperidone

Oncology

    --  Leukemia
    --  Vincristine
    --  Lymphoma
    --  Cytarabine
    --  Prostate
    --  Goserelin
    --  Leuprolide
    --  Triptorelin

Pain Management

    --  Bupivacaine

Reproductive Health

Endometriosis

Companies Mentioned

    --  Alkermes
    --  Amylin
    --  AntriaBio
    --  Ascendis Pharma
    --  AstraZeneca
    --  Aurobundo
    --  Avadel
    --  Biomarin
    --  Camurus
    --  Critical Pharmaceuticals
    --  DURECT
    --  Eli Lilly Enzon
    --  Ipsen
    --  Janssen
    --  NanOlogy
    --  Novartis
    --  OctoPlus
    --  Oakwood Laboratories
    --  PharmaSophia
    --  Pacira
    --  PhaseBio Pharmaceuticals
    --  Recipharm AB
    --  Roche
    --  Sanofi
    --  Taiwan Liposome Company
    --  Xbrane Biopharma
    --  Talon
    --  Octoplus
    --  Midatech
    --  MedinCell

For more information about this report visit https://www.researchandmarkets.com/r/uu5bjd

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:https://www.prnewswire.com/news-releases/sustained-release-injectables-markets-2028-301450705.html

SOURCE Research and Markets

Email

|

Slashdot

|

Digg

|

Del.icio.us

|

Feeds

RELATED NEWS ARTICLES

Asetek - Mandatory Notification of Trade | Jan 22, 2026 BC.GAME to Host "Stay Untamed" Night During Abu Dhabi's Packed Web3 Summit Week | Jan 22, 2026 Tomorrowland Brings the Magic to Shanghai for a Spectacular First Indoor Edition in China | Jan 22, 2026 Rent Manager Earned Best Real Estate Software Product Award and Multiple Review Badges from G2 Platform | Jan 22, 2026 Auburn University's Applied Research Institute Expands Advanced Manufacturing Capabilities with CF3D Enterprise Cell | Jan 22, 2026 California Divorce Mediation Center Unveils Modern Website Redesign | Jan 22, 2026 AMPERA ANNOUNCES LOCATION FOR GLOBAL HEADQUARTERS | Jan 22, 2026 Gemmy Alerts Customers: Fake Websites Target Holiday Decorators | Jan 22, 2026 AMPLIFY Named Finalist in Three Categories at the 2026 Golden Gavel Awards | Jan 22, 2026 Culture and tourism sectors thrive in Xiamen | Jan 22, 2026